Free Trial
NASDAQ:GHRS

GH Research Q2 2024 Earnings Report

GH Research logo
$22.94 0.00 (0.00%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$23.15 +0.21 (+0.92%)
As of 07:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GH Research EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.23
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

GH Research Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GH Research Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Monday, September 2, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

GH Research's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

GH Research Earnings Headlines

Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More GH Research Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GH Research? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GH Research and other key companies, straight to your email.

About GH Research

GH Research (NASDAQ:GHRS) is a clinical-stage biopharmaceutical company focused on developing novel treatments for psychiatric and neurological disorders. The company’s research centers on mebufotenin, also known as 5-MeO-DMT, a psychedelic compound being evaluated through proprietary formulations and delivery methods designed to produce rapid-acting therapeutic effects.

GH Research’s lead investigational program, GH001, is an inhaled formulation of mebufotenin being studied for major depressive disorder, including treatment-resistant depression. The company is also developing additional mebufotenin-based programs, including formulations intended for alternative routes of administration. These products remain investigational, and GH Research does not currently market an approved therapy.

Headquartered in Dublin, Ireland, GH Research conducts clinical development activities internationally through studies involving patients in multiple regions. The company’s programs are focused on addressing psychiatric conditions for which existing treatments may have limited effectiveness or a delayed onset of action.

View GH Research Profile